DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux

Cytometry

Volumn 25, Issue 1, 1996, Pages 14-20

  Minderman, Hans ^a   Vanhoefer, Udo ^b   Toth, Karoly ^a   Yin, Ming Biao ^a   Minderman, M Denice ^a   Wrzosek, Carol ^a   Slovak, Marilyn L ^c   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

DiOC2(3); Flow cytometry; MDR functional assays; MRP; P glycoprotein; Rhodamine 123

Indexed keywords

3,3' DIETHYLOXADICARBOCYANINE; 5 (4,6 DIMETHYL 1,3,2 DIOXAPHOSPHORINAN 2 YL) 2,6 DIMETHYL 4 (3 NITROPHENYL) 3 PYRIDINECARBOXYLIC ACID 2 (4 BENZHYDRYL 1 PIPERAZINYL)ETHYL ESTER P OXIDE; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE 123; UNCLASSIFIED DRUG; 3,3' DIETHYLOXACARBOCYANINE; 3,3'-DIETHYLOXACARBOCYANINE; CARBOCYANINE; FLUORESCENT DYE; NICOTINIC ACID DERIVATIVE; PHOSPHINE OXIDE DERIVATIVE; RHODAMINE; TUMOR PROTEIN;

ARTICLE; ASSAY; CONTROLLED STUDY; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR CELL LINE; CELL CULTURE; DRUG ANTAGONISM; FEMALE; METABOLISM; METHODOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; CARBOCYANINES; CYCLIC P-OXIDES; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; NEOPLASM PROTEINS; NICOTINIC ACIDS; P-GLYCOPROTEIN; RHODAMINE 123; RHODAMINES; TUMOR CELLS, CULTURED;

EID: 0029658513     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19960901)25:1<14::AID-CYTO2>3.0.CO;2-E     Document Type: Article

References (36)

1. Bailly J-D, Muller C, Jaffrezou J-P, Demur C, Cassar G, Bordier C, Laurent G: Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia 9:799-807, 1995.
2. Barrand MA, Rhodes T, Center MS, Twentyman PR: Chemosensitization and drug accumulation effects of cyclosporin-A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer 29:408-415, 1993.
3. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85-94, 1991.
4. Cole SPC, Downes HF, Slovak ML. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein. Br J Cancer 59:42-46, 1989.
5. Cole SPC. Multidrug resistance in small cell lung cancer. Can J Physiol Pharmacol 70:313-329, 1992.
6. Darzynkiewicz Z, Crissman HA (eds): Methods in Cell Biology, Vol. 33: Flow Cytometry. Academic Press, San Diego, 1990.
7. Deuchars KL, Du R, Naik M, Evernden-Porelle D, Kartner N, Van der Bliek A, Ling V: Expression of hamster P-glycoprotein and multidrug resistance in DNA mediated transformants of mouse LTA cells. Mol Cell Biol 7:718-724, 1987.
8. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M: Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80:2729-2734, 1992.
9. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG: Overexpression of Multidrug Resistance-accociated Protein (MRP) increases resistance to natural product drugs. Cancer Res 54:357-361, 1994.
10. Greco WR, Park HS, Rustum YM: An application of a new approach for the quantitation of drug synergism to the combination of cisdiamminedichloroplatinum and 1-beta-D-arabino-furanosylcytosine. Cancer Res 50:5318-5327, 1990.
11. Gros P, Ben Neriah Y, Croop JM, Housman DE: Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323:728-731, 1986.
12. Gros P, Fallows DA, Croop JM, Housman DE: Chromosome-mediated gene transfer of multidrug resistance. Mol Cell Biol 6:3785-3790, 1986.
13. Guild BC, Mulligan RC, Gros P, Housman DE: Retroviral transfer of a murine cDNA for multidrug resistance confers pleiotropic drug resistance to cells without prior drug selection. Proc Nat Acad Sci USA 85:1595-1599, 1988.
14. Jamali MAA, Yin M-B, Mazzoni A, Bankusli, Rustum YM: Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: Modulation by the tiapamil analog RO11-2933 Cancer Chemother Pharmacol 25:77-83, 1989.
15. Krishan A, Sridhar KS, Davila E, Vogel C, Sternheim: Patterns of anthracycline retention modulation in human tumor cells. Cytometry 8:306-314, 1987.
16. Lampidis TL, Munck J-N, Krishan A, Tapiero H: Reversal of resistance to rhodamine-123 in adriamycin resistant Friend leukemia cells. Cancer Res 45:2626-2631, 1985.
17. Leith CP, Chen I-M, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL: Correlation of Multidrug Resistance (MDR1) protein expression with functional Dye/Drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/Efflux+ and MDR+/efflux- cases. Blood 86:2329-2342, 1995.
18. Ludescher C, Thaler J, Drach D, Drach J, Spitaler M, Gattringer C, Huber H, Hoffman J: Detection of activity of P-glycoprotein in human tumour samples using rhodamine-123. Br J Haematol 82:161-168, 1992.
19. Marie J-P, Faussat-Suberville A-M, Zhou D, Zittoun R: Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr-1 expression. Leukemia 7:825-831, 1993.
20. Marsh W, Sicheri R, Center' MS: Isolation and characterization of adriamycin-resistant HL60 cells which are not defective in the initial intracellular accumulation of drug. Cancer Res 46:4053-4057, 1986.
21. Marsh W, Center MS: Adriamycin resistance in HL60 cells and accompanying modification of a surface membrane protein contained in drug-sensitive cells. Cancer Res 47:5080-5086, 1987.
22. Maslak P, Hegewisch-Becker S, Godfrey L, Andreeff M: Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia. Cytometry 17:84-93, 1994.
23. McGrath T, Latoud C, Arnold ST, Safa AR, Felsted RL, Center MS: Mechanisms of multidrug resistance in HL60 cells: analysis of resistance associated membrane proteins and levels of MDR gene expres-sion. Biochem Pharmacol 38:3611-3619, 1989.
24. McGrath T, Center MS: Adriamycin resistance in HL60 cells in the abscence of detectable P-glycoprotein. Biochem Biophys Res Commun 145:1171-1176, 1987.
25. Nooter K, Van Den Engh G, Sonneveld P: Quantitative flow cytometric determination of anthracycline content of rat bone marrow cells. Cancer Res 43:5126-5130, 1983.
26. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC: A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Nat Acad Sci USA 85:4486-4490, 1988.
27. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJLM, Clevers HC, Scheper RJ: The drug resistance related protein LRP is a major vault protein. Nature Med 1:578-582, 1995.
28. Scheper RJ, Broxterman HJ, Scheffer GL, Kaajik P, Dalton WS, van Heijningen THM, van Kalken CK, Slovak ML, de Vries EGE, van der Valk P, Meijer CJLM, Pinedo HM: Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53:1475-1479, 1993.
29. Shen D-W, Fojo AT, Roninson IB, Soffir R, Pastan I, Gottesman MM: Multidrug resistance of DNA mediated transformants is linked to transfer of the human mdr1 gene. Mol Cell Biol 6:4039-4045, 1986.
30. Shudo N, Mizoguchi T, Kiyosue T, Arita M, Yoshimura A, Seto K, Sakoda R, Akiyama S-i: Two pyridine analogues with more effective ability to reverse multidrug resistance and with lower calcium channel blocking activity than their dihydropyridine counterparts. Cancer Res 50:3055-3061, 1990.
31. Slovak ML, Hoeltge GA, Dalton WS, Trent JM: Pharmacoogical and biochemical evidence for differing mechanisms of doxorubicin resistance in two tumor cell lines. Cancer Res 48:2793-2797, 1988.
32. Speth P, Linssen P, Boezeman J, Wessels H, Haanen C: Quantification of anthracyclines in human hematopoietic cell subpopulations by flow cytometry and high pressure liquid chromatography. Cytometry 6:143-150, 1985.
33. Ueda K, Cardarelli C, Gottesman MM, Pastan I: Expression of a fulllength cDNA for the human "mdr-1" gene confers resistance to colchicine, doxorubicin and vinblastine. Proc Nat Acad Sci USA 84:3004-3008, 1987.
34. Vanhoefer U, Cao S, Minderman H, Toth K, Scheper RJ, Slovak ML, Rustum YM: PAK104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts overexpressing the multidrug resistance protein (MRP). Clinical Cancer Res 2:369-377, 1996.
35. Wadkins RM, Houghton PJ: Kinetics of transport of dialkyloxacarbocyanines in multidrug-resistant cell lines overexpressing P-glycoprotein: Interrelationship of dye alkyl chain length, cellular flux, and drug resistance. Biochemistry 34:3858-3872, 1995.
36. Yin MB, Arredondo MA, Guimaraes MA, Schober C, Rustum YM: Modulation of the in vitro cytotoxicity of doxorubicin in multidrug resistant cells with and without P-glycoprotein-expression. Cell Pharmacol 2:23-28, 1995.